The Wuxi (Mashan) National Life Sciences Park in Binhu district, Wuxi, Jiangsu province. [Photo/ourjiangsu.com]

The life sciences and healthcare industry in Binhu district, Wuxi, East China's Jiangsu province has been steadily growing over the past few years.

The gross output of the industry in the first five months of this year is expected to reach 4.56 billion yuan (680.44 million), up 2.5 percent year-on-year.

The district is presently home to more than 200 life sciences and healthcare companies, including Fresenius Kabi SSPC, Pfizer, Genesis MedTech, and Biocity, due to its complete industrial chain.

Biomedical companies in Binhu have also made significant achievements in product development and business expansion due to the district's continued efforts to boost innovation and high-quality development in the industry.

D3 Bio, a biotechnology company located in the Wuxi (Mashan) National Life Sciences Park, recently received approval from the US Food and Drug Administration to conduct clinical trials for its antitumor drug D3S-001, which has been proven to be remarkably effective in treating many cancers, including lung cancer and colorectal and pancreatic cancer.

Wuxi Biologics, also located in the park, signed an agreement with Binhu government on June 2 to build an innovation center, talent apartments and other facilities to promote research and development of biomedicines as well as international cooperation.